Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure.

Patients with heart failure with reduced ejection fraction (HFrEF) who received the sodium-glucose co-transport 2 inhibitor, dapagliflozin, in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) study have a significant reduction in worsening heart failure (HF) and cardiovascular death. It is uncertain what proportion of patients admitted to a large regional cardiac centre with decompensated heart failure would be eligible for dapagliflozin post-discharge based on their characteristics at discharge. The DAPA-HF study criteria were retrospectively applied to a cohort of 521 consecutive patients referred to the inpatient HF service in a tertiary cardiac centre in South West Wales between April 2017 and April 2018.

Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period.

Objectives: This study sought to characterize patients attending a community heart failure (HF) clinic and identified those who were eligible for optimization of beta-blockers (BB) or ivabradine.

Background: Among patients with HF due to left ventricular systolic dysfunction in sinus rhythm, those with higher resting heart rate have a worse prognosis. Reducing sinus rate to 50 to 60 beats/min might improve outcomes.

Case selection for cardiac resynchronization in atrial fibrillation.

Remarkably little evidence exists that cardiac resynchronization therapy (CRT) is effective in patients who have atrial fibrillation (AF) but who otherwise seem suitable for this treatment. The landmark trials of CRT generally excluded patients with AF because atrioventricular (AV) resynchronization was considered a possibly important mechanism by which CRT might deliver its benefits. The only landmark trial that included many patients with AF confirmed marked benefit among patients in sinus rhythm but no benefit among those with AF.